Skip to main content

Table 2 Changes in FMD (ΔFMD) in the sitagliptin and voglibose group

From: DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

Variable

Sitagliptin

Voglibose

Between-group difference

n = 24

n = 31

FMD (%)

   

  Baseline at 0 W

5.41 ± 2.25

4.96 ± 2.16

P = 0.450

  at 12 W

6.17 ± 2.00

5.94 ± 2.15

P = 0.692

  ΔFMD:12 W-0 W

0.76 ± 2.42

0.98 ± 2.41

P = 0.729

Adjusted ΔFMD:12 W-0 W*

1.11

0.98

P = 0.8316

  (95% CIs)

(0.07-2.16)

(0.04-1.91)

  1. Values are means ± SD or the least square means (95% CI). *The least square means (95% CIs) were derived from ANCOVA adjusted for the baseline FMD, age, sex, current smoking, diabetes duration and BMI.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840